Trial intelligence / Profile preview

CADILLACC trial of cemiplimab before and after chemoradiotherapy in locally advanced cervical carcinoma

2025-521839-36-00Phase 2Authorised

Sponsor: Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
Start: Nov 2026
Modality: Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
Countries: 1

Overview

Phase 2, open-label, single-arm trial of cemiplimab and cisplatin in Cervical Cancer (CC), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Objective response rate. Planned start Nov 2026; status: authorised.

Drugs

cemiplimabcisplatin

Conditions

Cervical Cancer (CC)

Beyond the preview

Go deeper on 2025-521839-36-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2025-521839-36-00.